{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:48:19Z","timestamp":1773298099502,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,31]],"date-time":"2016-12-31T00:00:00Z","timestamp":1483142400000},"content-version":"vor","delay-in-days":944,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurolog\u00eda"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.nrl.2013.06.014","type":"journal-article","created":{"date-parts":[[2013,9,10]],"date-time":"2013-09-10T12:49:51Z","timestamp":1378817391000},"page":"257-260","source":"Crossref","is-referenced-by-count":8,"title":["Experiencia cl\u00ednica con los cannabinoides en la terapia de la espasticidad en la esclerosis m\u00faltiple"],"prefix":"10.1016","volume":"29","author":[{"given":"L.","family":"Lorente Fern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Monte Boquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"P\u00e9rez-Miralles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Gil G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Escutia Roig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bosc\u00e1 Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Poveda Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Casanova-Estruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrl.2013.06.014_bib0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","article-title":"Prevalence and treatment of spasticity reported by multiple sclerosis patients","volume":"10","author":"Rizzo","year":"2004","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.06.014_bib0010","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/00207454.2012.762364","article-title":"Spasticity in multiple sclerosis: Results of a patient survey","volume":"123","author":"Oreja-Guevara","year":"2013","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.nrl.2013.06.014_bib0015","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0035-3787(12)70047-4","article-title":"Spasticity and everyday life in multiple sclerosis","volume":"168","author":"Donz\u00e9","year":"2012","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.nrl.2013.06.014_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7400","article-title":"Treatments for spasticity and pain in multiple sclerosis: A systematic review","volume":"7","author":"Beard","year":"2003","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.nrl.2013.06.014_bib0025","first-page":"CD001332","article-title":"Anti-spasticity agents for multiple sclerosis","volume":"4","author":"Shakespeare","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nrl.2013.06.014_bib0030","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.2174\/138161208785740036","article-title":"The endocannabinoid system and multiple sclerosis","volume":"14","author":"Baker","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nrl.2013.06.014_bib0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2174\/1389557054368790","article-title":"The role of cannabinoid system on immune modulation: Therapeutic implications on CNS inflammation","volume":"5","author":"Correa","year":"2005","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.nrl.2013.06.014_bib0040","unstructured":"Ficha t\u00e9cnica Sativex\u00ae (delta-9-tetrahidrocannabinol\/cannabidiol) [consultado 1 Feb 2013]. European Medicines Agency. Disponible en: http:\/\/www.aemps.gob.es\/cima\/especialidad.do?metodo=verFichaWordPdf&codigo=72544&formato=pdf&formulario=FICHAS&file=ficha.pdf"},{"key":"10.1016\/j.nrl.2013.06.014_bib0045","first-page":"421","article-title":"Tratamiento de la espasticidad en la esclerosis m\u00faltiple: nuevas perspectivas con el uso de cannabinoides","volume":"55","author":"Oreja-Guevara","year":"2012","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrl.2013.06.014_bib0050","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex\u00ae), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nrl.2013.06.014_bib0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3233\/NRE-2009-0487","article-title":"A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis","volume":"24","author":"Anwar","year":"2009","journal-title":"Neurorehabilitation"},{"key":"10.1016\/j.nrl.2013.06.014_bib0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","journal-title":"Phys Ther"},{"key":"10.1016\/j.nrl.2013.06.014_bib0065","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/jnnp.2009.177071","article-title":"Stop using the Ashworth Scale for the assessment of spasticity","volume":"81","author":"Fleuren","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nrl.2013.06.014_bib0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1352458511419700","article-title":"A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex\u00ae (nabiximols)","volume":"18","author":"Notcutt","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrl.2013.06.014_bib0075","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/ern.11.47","article-title":"THC and CBD oromucosal spray (Sativex\u00ae) in the management of spasticity associated with multiple sclerosis","volume":"11","author":"Sastre-Garriga","year":"2011","journal-title":"Expert Rev Neurother"}],"container-title":["Neurolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485313001606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213485313001606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T18:38:52Z","timestamp":1596479932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213485313001606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0213485313001606"],"URL":"https:\/\/doi.org\/10.1016\/j.nrl.2013.06.014","relation":{},"ISSN":["0213-4853"],"issn-type":[{"value":"0213-4853","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}